UC San Diego Viral Hepatitis and Hepatocellular Carcinoma Symposium (HCC)

Venue: UC San Diego Skaggs School of Pharmacy, Health Sciences Education Center

Location: La Jolla, California, United States

Event Date/Time: Oct 01, 2011 End Date/Time: Oct 01, 2011
Registration Date: Oct 01, 2011
Report as Spam


Hepatocellular carcinoma (HCC) is the third most common cause of global cancer-related deaths. HCC occurs in the setting of underlying liver disease, including hepatitis B (HBV) and C (HCV), nonalcoholic fatty liver disease (NASH), and alcoholic cirrhosis. The incidence of HCC in the United States has almost doubled in recent decades due to the increased prevalence of HCV, migration from endemic areas, and increasingly, NASH.
Treatment for HBV and HCV has changed dramatically in the last decade. New potent protease inhibitors are now available for HCV treatment. Treatment for viral hepatitis has changed substantially and understanding patient selection and response guided therapy is critical. In addition, treatment of the underlying liver disease as well as proper surveillance is imperative to prevent or treat early HCC.

This course provides a review and discussion of new treatments for viral hepatitis and an overview of HCC.

Three internationally renowned invited speakers and UCSD faculty from hepatology, surgery, radiology, pathology, and medical oncology will discuss new approaches to viral hepatitis and HCC.

Participants will learn about recent developments and future therapies for HCV and HBV, who is at risk of developing HCC, how to apply HCC surveillance, and analyze various treatment options from surgery to new targeted therapy to improve patients' outcome. This program is designed for the primary care practitioner, gastroenterologists, oncologists, infectious disease, including MDs, PAs and NPs.


Additional Information

Registration fees: Physicians $50 Allied Health $35